Shuo Ma
Hematology & Oncology · Chicago, ILNPI 1659564938
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 28.7% of the total. Among hematology & oncology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 175 payments — averaging $1598.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$80K
- Beigene USA, Inc.$53K
- Lilly USA, LLC$32K
- Johnson & Johnson$27K
- AbbVie$22K
- Genentech, Inc.$14K
- plus $51K from 13 others
Across 611 payments — averaging $33,030 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$11.6M
- Eli Lilly$1.6M
- Beigene AUS Pty Ltd$1.6M
- Beigene USA, Inc.$1.2M
- Bristol Myers Squibb$1.1M
- Beone Medicines USA, Inc.$902K
- plus $2.2M from 8 others
What the payments were for
- Consulting fees$106,54938%
- Speaking & faculty fees$164,84259%
- Travel & lodging$6,3522%
- Food & beverage$2,0341%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 59 | $80,345 |
| Beigene USA, Inc. | 22 | $53,175 |
| Lilly USA, LLC | 14 | $32,200 |
| Johnson & Johnson | 14 | $27,046 |
| AbbVie | 22 | $22,155 |
| Genentech, Inc. | 13 | $14,076 |
| Beone Medicines USA, Inc. | 4 | $10,645 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $9,800 |
| Gilead | 3 | $5,490 |
| Eli Lilly | 2 | $4,525 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,498 |
| Astrazeneca UK Limited | 1 | $3,425 |
| Genentech USA, Inc. | 4 | $3,166 |
| Janssen Scientific Affairs, LLC | 2 | $2,778 |
| F. Hoffmann-la Roche AG | 2 | $2,352 |
| Invivyd Inc | 1 | $2,100 |
| Verastem, Inc. | 1 | $1,980 |
| Foundation Medicine, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$279,798 in reported general payments places this provider in the 95th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 117 | $1,471,527 |
| CalquenceAcalabrutinib Maleate | 97 | $1,447,060 |
| VenclextaVenetoclax | 25 | $350,659 |
| PromactaEltrombopag Olamine | 13 | $174,132 |
| EliquisApixaban | 19 | $15,030 |
| Atovaquone | 17 | $8,057 |
| Acyclovir | 295 | $4,254 |
| PaxlovidNirmatrelvir/Ritonavir | 17 | $1,462 |
| Allopurinol | 62 | $708 |
| ValacyclovirValacyclovir Hcl | 23 | $643 |
| Entecavir | 14 | $427 |
| Pantoprazole Sodium | 16 | $109 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $53,175 | $1,471,527117 claims |
| AstraZenecaCalquence | $80,345 | $1,447,06097 claims |
| AbbVieVenclexta | $22,155 | $350,65925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
- Reem KarmaliChicago$272K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.